Kansas City, Mo. — July 21, 2026 — Felixvet Inc. today announced the commercial availability of Firocoxib Tablets for Horses, an FDA-approved non-steroidal anti-inflammatory drug (NSAID) indicated for the control of pain and inflammation associated with osteoarthritis in horses. Approved by the U.S. Food and Drug Administration on February 23, 2026, under ANADA 200-841, the product expands Felixvet’s growing animal health portfolio and provides veterinarians and horse owners with an important treatment option for managing equine osteoarthritis.
Product Details
“We’re excited to expand Felixvet’s portfolio into the equine market with the introduction of Firocoxib Tablets for Horses,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels, Felixvet. “Osteoarthritis is one of the most common causes of pain and reduced mobility in horses, and we’re proud to provide veterinarians and horse owners with an FDA-approved treatment option that helps support equine comfort and performance.”
Osteoarthritis is one of the most common causes of chronic pain and reduced mobility in horses. Firocoxib Tablets for Horses are administered once daily for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses.
The product is therapeutically equivalent to the pioneer drug and provides the same safety and efficacy profile. Available as a 57 mg chewable tablet, Firocoxib Tablets for Horses feature a palatable beef flavor and a scored tablet design to support easy administration and accurate dosing. The product is available in 60-count and 180-count bottle presentations.
“At Felixvet, we’re committed to bringing high-quality veterinary medicines to market that address meaningful needs across animal health,” added Lauren Landolph. “The addition of Firocoxib Tablets for Horses reflects our continued investment in providing trusted treatment options for veterinarians, horse owners, and the animals in their care.”
Felixvet continues to expand its portfolio of FDA-approved animal health products, supporting veterinarians and animal owners with high-quality, accessible treatment options across companion animal and equine therapeutic categories.
For additional information, please contact info@felixvet.com
About Felixvet
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix develops and commercializes high-quality, bioequivalent pharmaceutical products for companion animals. The company is focused on expanding access to FDA-approved veterinary medicines through a growing portfolio of trusted treatment options for veterinarians and pet owners.
Media Contact
Paula Flavin
Project Marketing Manager, US Operations
D: 816-912-2000
E: info@felixvet.com
